Click Here To Register Now!
2024 NIH, National Institute on Aging Director’s Regional Meeting
read more
News and Events
2024 NIH, National Institute on Aging Director’s Regional Meeting
The post 2024 NIH, National Institute on Aging Director’s Regional Meeting appeared first on Arizona Alzheimer's Consortium.
New Alzheimer’s prevention trial receives $74.5 million NIH grant
Two-part trial to build on landmark Colombian prevention study of people at near-certain genetic risk for early-onset Alzheimer’s disease PHOENIX (Thursday, Nov. 14) – A new Alzheimer’s prevention study has received a $74.5 million five-year grant from the National...
Arizona Alzheimer’s Consortium (AAC) Biomarker Measurement Support Request for Proposals
APPLICATION RECEIPT DATE: Recommended: Pre-proposal Deadline: November 1, 2024 (Friday) Full Application Deadline: December 11, 2024 Anticipated Analysis Start Date: February 3, 2025 (Wednesday) PURPOSE: The Arizona Alzheimer’s Consortium (AAC) invites applications...
Los hispanos son 50% más propensos a contraer una enfermedad de demencia, según experto
Hay alrededor de 10 variaciones de enfermedades de demencia y la más común es el Alzheimer. Haga clic aquí para leer la historia completa. | Click Here to Read the Full Story The post Los hispanos son 50% más propensos a contraer una enfermedad de demencia, según...
ASU awarded prestigious $5.8 million NIH Roybal Center
Living alone is a lesser-known risk factor for Alzheimer’s and other types of cognitive decline. With an estimated 14 million Americans aging solo — by choice or circumstance — Arizona State University has a plan to help and new funding to support it. This summer,...
Dr. David W. Coon awarded the M. Powell Lawton Award by the American Psychological Association’s Society of Clinical Geropsychology
Dr. David W. Coon, director of Arizona State University’s Center for Innovation in Healthy and Resilient Aging and associate dean of ASU’s Edson College of Nursing and Health Innovation, was awarded the M. Powell Lawton Award by the American Psychological...
FDA approves donanemab; Banner Alzheimer’s trial participants interviewed in N.Y. Times
FDA approves donanemab; Banner Alzheimer’s trial participants interviewed in N.Y. Times The FDA on Tuesday approved a new drug for Alzheimer’s disease, and clinical trials at both Banner Alzheimer’s Institute locations and Banner Sun Health Research Institute provided...
Banner Health hires renowned leader for new biomarker research program
Nicholas Ashton’s program aims to discover, galvanize use of new blood tests in fight against Alzheimer’s and related diseases PHOENIX (May 15, 2024) – Emerging blood tests have begun to revolutionize the fight against Alzheimer’s disease, the most common cause of...